ICN Pharmaceuticals Acquires Solco

Costa Mesa drug maker ICN Pharmaceuticals Inc. said Wednesday it acquired Swiss pharmaceutical company Solco Basel AG. Financial terms weren’t disclosed.

ICN said privately held Solco, which sells dermatology, skin-care, wound-healing and ophthalmology products in Europe, the Middle East and Asia, had sales of $28 million in 1999. Last year, ICN earned $118.6 million, or $1.45 a diluted share, on revenue of $747.4 million.

ICN’s stock rose 13 cents a share to $28.56 on the New York Stock Exchange.